Barbora de Courten1,2, José Maria Moreno-Navarrete3, Jasmine Lyons1, Georgia Soldatos1,2, Maximilian de Courten4, Sonia Dougherty1, Josephine Forbes1,4,5,6, José Manuel Fernández-Real3. 1. Baker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia. 2. Monash Centre for Health, Research and Implementation (MCHRI), School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia. 3. University Hospital of Girona, Institut d'Investigació Biomèdica de Girona (IDIBGi) and CIBERobn Pathophysiology of Obesity and Nutrition, Spain. 4. Centre for Chronic Disease, College of Health and Biomedicine, Victoria University, Melbourne, Australia. 5. Mater Research at TRI, Woolloongabba, Australia. 6. Mater Clinical School, University of Queensland, St Lucia, Australia.
Abstract
SCOPE: In experimental studies, moderate to high concentrations of sCD14 (serum cluster of differentiation 14 protein) prevent lipopolysaccharide (LPS)-induced systemic inflammation, while low concentrations may promote inflammation. Given that metabolic endotoxemia is thought to initiate high-fat diet-induced insulin resistance, we explored the association between sCD14 concentrations and insulin sensitivity in humans. METHODS AND RESULTS: Healthy non-obese (n = 12, BMI 26 ± 5y), obese (n = 11, BMI 33.45 ± 3.2) and morbidly obese participants (n = 38, BMI 45 ± 7) underwent measurement of body composition (dual energy X-ray absorptiometry) and a hyperinsulinemic-euglycemic clamp to measure insulin sensitivity (M value). Circulating sCD14 concentrations were measured by ELISA. Non-obese participants had lower circulating sCD14 concentrations compared to obese (p = 0.03). Circulating sCD14 concentrations were positively associated with percent body fat, waist circumference and white blood cell count and negatively associated with insulin sensitivity. In contrast, circulating sCD14 were positively associated with insulin sensitivity in morbidly obese participants. In regression analysis, insulin sensitivity (r = 0.52, p = 0.004) and fasting triglycerides (r = 0.49, p = 0.005) contributed independently to circulating sCD14 variance after controlling for age, sex and BMI in these morbidly obese subjects. CONCLUSION: These findings suggest that circulating sCD14 concentrations, through its compensatory (in non-obese subjects) or buffering role (in morbidly obese subjects), could exert an important role in modulating insulin sensitivity.
SCOPE: In experimental studies, moderate to high concentrations of sCD14 (serum cluster of differentiation 14 protein) prevent lipopolysaccharide (LPS)-induced systemic inflammation, while low concentrations may promote inflammation. Given that metabolic endotoxemia is thought to initiate high-fat diet-induced insulin resistance, we explored the association between sCD14 concentrations and insulin sensitivity in humans. METHODS AND RESULTS: Healthy non-obese (n = 12, BMI 26 ± 5y), obese (n = 11, BMI 33.45 ± 3.2) and morbidly obeseparticipants (n = 38, BMI 45 ± 7) underwent measurement of body composition (dual energy X-ray absorptiometry) and a hyperinsulinemic-euglycemic clamp to measure insulin sensitivity (M value). Circulating sCD14 concentrations were measured by ELISA. Non-obeseparticipants had lower circulating sCD14 concentrations compared to obese (p = 0.03). Circulating sCD14 concentrations were positively associated with percent body fat, waist circumference and white blood cell count and negatively associated with insulin sensitivity. In contrast, circulating sCD14 were positively associated with insulin sensitivity in morbidly obeseparticipants. In regression analysis, insulin sensitivity (r = 0.52, p = 0.004) and fasting triglycerides (r = 0.49, p = 0.005) contributed independently to circulating sCD14 variance after controlling for age, sex and BMI in these morbidly obese subjects. CONCLUSION: These findings suggest that circulating sCD14 concentrations, through its compensatory (in non-obese subjects) or buffering role (in morbidly obese subjects), could exert an important role in modulating insulin sensitivity.
Authors: Sanyog G Shitole; Mary L Biggs; Alexander P Reiner; Kenneth J Mukamal; Luc Djoussé; Joachim H Ix; Joshua I Barzilay; Russell P Tracy; David Siscovick; Jorge R Kizer Journal: Diabetes Care Date: 2019-08-30 Impact factor: 19.112
Authors: Sahera Dirajlal-Fargo; Carlee Moser; Todd T Brown; Theodoros Kelesidis; Michael P Dube; James H Stein; Judith Currier; Grace A McComsey Journal: Open Forum Infect Dis Date: 2016-08-29 Impact factor: 3.835
Authors: Hiroyuki Hoshiko; Edith J M Feskens; Els Oosterink; Renata M C Ariens; Jurriaan J Mes; Nicole J W de Wit Journal: Metabolites Date: 2021-12-16